Stevens Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Stevens Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-26,503	Closed	-$405K	–	1248
2016 Q1	$405K	Buy	+26,503	New	+$415K	0.02%	614
2015 Q4	–	Sell	-19,838	Closed	-$346K	–	1278
2015 Q3	$346K	Buy	+19,838	New	+$404K	0.02%	648
2014 Q1	–	Sell	-13,404	Closed	-$135K	–	1449
2013 Q4	$135K	Buy	+13,404	New	+$162K	﹤0.01%	952

Other funds holding AMRI

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Stevens Capital Management's AMRI Position: Q2 2016 in Review

Stevens Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q2 2016, closing a stake of 26,503 shares — an estimated $405K sold.

Stevens Capital Management first reported a position in AMRI in Q4 2013 and held it in 3 quarters. The position peaked at $405K in Q1 2016. 142 funds tracked by Wall St. Rank hold AMRI as of Q2 2016.

Stevens Capital Management reported no remaining Albany Molecular Research Inc position as of Q2 2016 after selling out during the quarter.
Stevens Capital Management sold 26,503 Albany Molecular Research Inc shares in Q2 2016, an estimated $405K.
Stevens Capital Management first reported a position in Albany Molecular Research Inc in Q4 2013 and held it in 3 quarters.
Stevens Capital Management's Albany Molecular Research Inc position peaked at $405K in Q1 2016.
142 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2016.

Based on Stevens Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.